Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Decreasing the incidence of chronic rejection and reducing the need for life-long immunosuppression remain important goals in clinical transplantation. In this article, we will review how regulatory T cells (Treg) came to be recognized as an attractive way to prevent or treat allograft rejection, the ways in which Treg can be manipulated or expanded in vivo, and the potential of in vitro expanded/generated Treg for cellular therapy. We will describe the first regulatory T cell therapies that have been or are in the process of being conducted in the clinic as well as the safety concerns of such therapies and how outcomes may be measured.

Original publication




Journal article


Semin Immunol

Publication Date





304 - 313


Animals, Cell- and Tissue-Based Therapy, Chemotherapy, Adjuvant, Clinical Trials as Topic, Europe, Graft Rejection, Humans, Immunomodulation, Organ Transplantation, T-Lymphocytes, Regulatory, Transplantation Tolerance, Treatment Outcome